Remedy Entertainment Oyj Statistics
Total Valuation
HEL:REMEDY has a market cap or net worth of EUR 179.51 million. The enterprise value is 169.50 million.
| Market Cap | 179.51M | 
| Enterprise Value | 169.50M | 
Important Dates
The last earnings date was Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
HEL:REMEDY has 13.64 million shares outstanding. The number of shares has increased by 0.56% in one year.
| Current Share Class | 13.64M | 
| Shares Outstanding | 13.64M | 
| Shares Change (YoY) | +0.56% | 
| Shares Change (QoQ) | +4.09% | 
| Owned by Insiders (%) | 44.96% | 
| Owned by Institutions (%) | 8.31% | 
| Float | 5.50M | 
Valuation Ratios
The trailing PE ratio is 279.75 and the forward PE ratio is 77.41.
| PE Ratio | 279.75 | 
| Forward PE | 77.41 | 
| PS Ratio | 3.00 | 
| PB Ratio | 2.58 | 
| P/TBV Ratio | 3.14 | 
| P/FCF Ratio | 15.47 | 
| P/OCF Ratio | 38.95 | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.44, with an EV/FCF ratio of 14.61.
| EV / Earnings | 265.26 | 
| EV / Sales | 2.83 | 
| EV / EBITDA | 18.44 | 
| EV / EBIT | 91.97 | 
| EV / FCF | 14.61 | 
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.25.
| Current Ratio | 3.93 | 
| Quick Ratio | 3.93 | 
| Debt / Equity | 0.25 | 
| Debt / EBITDA | 1.91 | 
| Debt / FCF | 1.51 | 
| Interest Coverage | 1.44 | 
Financial Efficiency
Return on equity (ROE) is 0.95% and return on invested capital (ROIC) is 1.47%.
| Return on Equity (ROE) | 0.95% | 
| Return on Assets (ROA) | 1.23% | 
| Return on Invested Capital (ROIC) | 1.47% | 
| Return on Capital Employed (ROCE) | 2.13% | 
| Revenue Per Employee | 155,405 | 
| Profits Per Employee | 1,660 | 
| Employee Count | 367 | 
| Asset Turnover | 0.64 | 
| Inventory Turnover | n/a | 
Taxes
In the past 12 months, HEL:REMEDY has paid 988,000 in taxes.
| Income Tax | 988,000 | 
| Effective Tax Rate | 60.73% | 
Stock Price Statistics
The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.69, so HEL:REMEDY's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 | 
| 52-Week Price Change | -16.81% | 
| 50-Day Moving Average | 13.94 | 
| 200-Day Moving Average | 14.81 | 
| Relative Strength Index (RSI) | 44.81 | 
| Average Volume (20 Days) | 6,608 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, HEL:REMEDY had revenue of EUR 59.83 million and earned 639,000 in profits. Earnings per share was 0.05.
| Revenue | 59.83M | 
| Gross Profit | 45.69M | 
| Operating Income | 1.84M | 
| Pretax Income | 1.63M | 
| Net Income | 639,000 | 
| EBITDA | 7.81M | 
| EBIT | 1.84M | 
| Earnings Per Share (EPS) | 0.05 | 
Balance Sheet
The company has 27.56 million in cash and 17.55 million in debt, giving a net cash position of 10.01 million or 0.73 per share.
| Cash & Cash Equivalents | 27.56M | 
| Total Debt | 17.55M | 
| Net Cash | 10.01M | 
| Net Cash Per Share | 0.73 | 
| Equity (Book Value) | 69.57M | 
| Book Value Per Share | 5.10 | 
| Working Capital | 31.91M | 
Cash Flow
In the last 12 months, operating cash flow was 4.61 million and capital expenditures 7.00 million, giving a free cash flow of 11.60 million.
| Operating Cash Flow | 4.61M | 
| Capital Expenditures | 7.00M | 
| Free Cash Flow | 11.60M | 
| FCF Per Share | 0.85 | 
Margins
Gross margin is 76.36%, with operating and profit margins of 3.08% and 1.07%.
| Gross Margin | 76.36% | 
| Operating Margin | 3.08% | 
| Pretax Margin | 2.72% | 
| Profit Margin | 1.07% | 
| EBITDA Margin | 13.06% | 
| EBIT Margin | 3.08% | 
| FCF Margin | 19.39% | 
Dividends & Yields
HEL:REMEDY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -0.56% | 
| Shareholder Yield | -0.56% | 
| Earnings Yield | 0.36% | 
| FCF Yield | 6.46% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | 
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
HEL:REMEDY has an Altman Z-Score of 5.74 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.74 | 
| Piotroski F-Score | 7 |